Treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs failed to mitigate bone mineral density ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Please provide your email address to receive an email when new articles are posted on . Demographic factors were significantly associated with slower or faster initiation of b/ts DMARDs for RA.

CHICAGO -- The current mantra of hitting rheumatoid arthritis (RA) hard and early should not equate to starting patients on biologic therapies right out of the gate, a prominent RA specialist said ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...

If your gut is telling you that your disease-modifying antirheumatic drugs (DMARDs) aren't working as well as they should, listen to it. Rebecca B. Blank, MD That's the advice of Rebecca B. Blank, MD, ...

Only a decade ago, prior to the availability of anti-TNF agents and other BRMs, most patients with RA were treated with MTX and other DMARDs. Although many patients with RA responded relatively well ...

Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...